duloxetin krka 90 mg tvrdé gastrorezistentné kapsuly
krka, d.d., novo mesto, slovinsko - duloxetín - 30 - antidepressiva
dulsevia 90 mg tvrdé gastrorezistentné kapsuly
krka, d.d., novo mesto, slovinsko - duloxetín - 30 - antidepressiva
ambroxol al kvapky
stada arzneimittel ag, nemecko - ambroxol - 52 - expectorantia, mucolytica
jodid draselný 65 hameln
hameln rds s. r. o., slovensko - jodid draselný - 19 - antidota, detoxicantia
mucosin tablety
sanofi-aventis slovakia s.r.o., slovensko - ambroxol - 52 - expectorantia, mucolytica
asolfena 5 mg
krka, d.d., novo mesto, slovinsko - solifenacín - 73 - spasmolytica
asolfena 10 mg
krka, d.d., novo mesto, slovinsko - solifenacín - 73 - spasmolytica
tramadol/paracetamol xantis 75 mg/650 mg tablety
xantis pharma limited, cyprus - tramadol a paracetamol - 65 - analgetica - anodyna
paralen grip
opella healthcare slovakia s.r.o., slovensko - paracetamol, kombinácie s výnimkou psycholeptík - 07 - analgetica, antipyretica
darzalex
janssen-cilag international n.v. - daratumumab - viacnásobný myelóm - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. v kombinácii s bortezomib, talidomid a dexamethasone na liečbu dospelých pacientov s novo diagnostikovanou myelómom je mladších, ktorí majú nárok na autológne transplantácii kmeňových buniek. v kombinácii s lenalidomide a dexamethasone, alebo bortezomib a dexamethasone, na liečbu dospelých pacientov s mnohopočetným myelómom, ktorí dostali aspoň jeden pred terapia. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. ako monotherapy na liečbu dospelých pacientov s relapsed a žiaruvzdorné myelómom je mladších, ktorých pred terapia súčasťou proteasome inhibítor a imunomodulačné agent a ktorí preukázali progresii ochorenia na poslednej terapia. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.